We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapy.
- Authors
Seung-hwan Jeong; Sang Eun Yeon; Su Youn Kim; Tae Gyun Kwon; Seong Soo Jeon; Young Deuk Choi; Dongdeuk Kwon; Byung Ha Chung; Sung-Hoo Hong; Byung Hoon Kim; Hyo Jin Lee; Sang Joon Shin; Woo Suk Choi; Sung Woo Park; Taek Won Kang; Seok Joong Yun; Jin Seon Cho; See Min Choi; Na-Ri Lee; Cheol Kwak
- Abstract
Purpose: The proper treatment sequence for administering abiraterone acetate plus prednisolone (AAP) and chemotherapeutic agents has not yet been elucidated for metastatic castration-resistant prostate cancer (mCRPC). Hence, this study evaluated the effectiveness and safety of AAP in pre- and post-chemotherapy settings using real-world data. Materials and Methods: This prospective, multicenter, open-label, observational study included 506 patients with mCRPC. Patients were classified according to the timing of chemotherapy into pre- and post-chemotherapy groups. The effectiveness and safety of AAP were compared between the groups; the prostate-specific antigen (PSA) response, PSA progression-free survival, and radiologic progression-free survival were assessed; and adverse drug reactions were recorded. Results: Among the included patients, 319 and 187 belonged to the pre- and post-chemotherapy groups, respectively. Risk classification was similar between the two groups. The PSA response was 61.8% in the pre-chemotherapy group and 39.0% in the postchemotherapy group (p<0.001). The median time to PSA progression (5.00 vs. 2.93 mo, p=0.001) and radiologic progression-free survival (11.84 vs. 9.17 mo, p=0.002) were significantly longer in the pre-chemotherapy group. Chemotherapy status was associated with PSA (hazard ratio [HR] 1.39, 95% confidence interval [CI] 1.09–1.77) and radiologic progression (HR 1.66, 95% CI 1.18–2.33) during AAP treatment. Adverse drug reactions were reported at similar frequencies in both groups. Conclusions: In this postmarketing surveillance, AAP benefited patients with mCRPC, especially in settings before chemotherapy was administered, resulting in a high PSA response and longer PSA and radiologic progression-free survival with tolerable adverse drug reactions.
- Subjects
SOUTH Korea; CASTRATION-resistant prostate cancer; DRUG side effects; PROSTATE-specific antigen; ABIRATERONE acetate; PROGRESSION-free survival
- Publication
Investigative & Clinical Urology, 2023, Vol 64, Issue 5, p466
- ISSN
2466-0493
- Publication type
Article
- DOI
10.4111/icu.20230128